tirzepatide and naion Zepbound | Free Case Evaluation Although rare, GLP-1s tied to

Stopping Ozempic often leads to weight regain, but research shows that continuing GLP-1 therapyor switching to a compounded alternativecan help sustain your results long-term

Taking Ozempic, Wegovy or a GLP-1

ESG has been shown to influence metabolic pathways, as demonstrated in the MERIT study (The Lancet, 2022), suggesting may offer similar metabolic benefits as a manual ESG approach

Taking Ozempic or another GLP-1

A new study uncovered an association between glucagon-like peptide-1 receptor agonist (GLP-1RAs) use and an increased risk of gastroparesis (GP) among patients with Type 2 diabetes.

This guide covers current clinical evidence, milk transfer concerns, and how to evaluate alternatives with your care team